Further validation of the efficacy of mesenchymal stem cell infusions for reducing mortality in COVID-19 patients with ARDS

Recent double-blind, randomized, controlled trials reported that human umbilical cord-derived mesenchymal stem cell (MSC) infusions in COVID-19 patients with acute respiratory distress syndrome (ARDS) could diminish cytokine storm and lung damage. While these outcomes are significant, additional phase II/III trials are required to validate the efficacy of MSCs to improve the survival of COVID-19 patients with ARDS. Future studies also need to assess the efficacy of MSCs to prevent long COVID.

Automated summary

Recent trials have shown that infusions of human umbilical cord-derived MSCs can reduce cytokine storm and lung damage in COVID-19 patients with ARDS. Further phase II/III trials are needed to confirm this efficacy and evaluate the potential of MSCs in preventing long-term COVID effects.